Table 1.

Patients and baseline disease characteristics split by anti-CCP status and gender

	All patients			Women			Men
	Anti-CCP		p value	Anti-CCP		p value	Anti-CCP		p value
	Positive	Negative		Positive	Negative		Positive	Negative
	n = 378	n = 279		n = 244	n = 184		n = 134	n = 95
Age, years	56	58	0.23	55	54	0.33	58	65	0.01
Disease duration, months	6	6	0.06	6	6	0.13	6	6	0.23
Ever smokers, %	66	55	0.006	61	51	0.046	74	63	0.07
BMI, kg/m2	25.4	25.5	0.60	24.9	25.5	0.23	26.0	25.5	0.36
RF-positivity, %	88	21	0.001	85	16	0.001	86	14	0.001
DAS28	5.3	5.2	0.19	5,3	5,3	0.66	5.2	4.9	0.10
Swollen joints, n	10	11	0.053	10	11	0.08	11	11	0.39
Tender joints, n	7	9	0.007	8	10	0.004	7	7	0.66
Patient global assessment VAS (0–100), mm	46	45	0.71	49	48	0.69	41	40	0.83
ESR, mm	41	31	0.001	41	30	0.001	41	32	0.001
CRP, mg/l	24	16	0.001	20	14	0.001	29	24	0.040
Pain VAS (0–100), mm	49	45	0.020	51	47	0.15	47	40	0.042
Pain VAS > 40 mm %	65	56	0.021	66	59	0.13	62	50	0.07
HAQ (0–3)	1.0	1.0	0.17	1.2	1.0	0.10	0.9	0.8	0.82

p values denote differences between groups. The values are mean (normally distributed) unless otherwise stated. Italicized p values are significant. Anti-CCP positivity titer > 25 IU/ml

BMI body mass index, RF rheumatoid factor, DAS28 28 joints-Disease Activity Score, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analogue scale, HAQ Health Assessment Questionnaire